PubMed Health⌕ Search

Biomedical subjects

Hidetaka Nakai

Publications and source records attributed to Hidetaka Nakai.

9 recordsLinked to original sources
PubMed2005

Synthesis and crystal structure of an open capsule-type octanuclear heterometallic sulfide cluster with a linked incomplete double cubane framework without an intramolecular inversion center.

An open capsule-type octanuclear heterometallic sulfide cluster without an intramolecular inversion center [Ru(eta(6)-C(6)Me(6)){P(OMe)(3)}{MoO(mu(3)-S)(3)}(CuI)(2)](2) (5) has been synthesized for the first time by stepwise connection of three mononuclear building blocks, i.e., (i) [RuCl(2)(eta(6)-C(6)Me(6)){P(OMe)(3)}] (1a) as an octahedral terminal building block to control the direction of cluster expansion, (ii) [MoOS(3)](2)(-) as a tetrahedral polydentate building block owing to the strong coordination ability of the S atoms, and (iii) a CuI building block to form a trigonal planar (mu-S)(2)CuI unit or to form a linkage unit of two incomplete cubane-type octanuclear frameworks. The stepwise connection was made in the following order: [RuCl(2)(eta(6)-C(6)Me(6)){P(OMe)(3)}] (1a, mononuclear) --> [Ru(eta(6)-C(6)Me(6)){P(OMe)(3)}{MoOS(mu(2)-S)(2)}] (2a, dinuclear) --> [Ru(eta(6)-C(6)Me(6)){P(OMe)(3)}{MoO(mu(2)-S)(2)(mu(3)-S)}CuI] (3a, butterfly-type trinuclear) --> [Ru(eta(6)-C(6)Me(6)){P(OMe)(3)}{MoO(mu(3)-S)(3)}(CuI)(2)](2) (5). When P(OMe)(3) was replaced by P(OEt)(3), which is more bulky than P(OMe)(3), in the starting ruthenium building block [RuCl(2)(eta(6)-C(6)Me(6)){P(OEt)(3)}] (1b, mononuclear), only the tetranuclear incomplete single cubane cluster [Ru(eta(6)-C(6)Me(6)){P(OEt)(3)}{MoO(mu(3)-S)(3)}(CuI)(2)] (6) was generated, owing to the steric effect of P(OEt)(3).

Crystallization↗
PubMed2004

A linear, O-coordinated eta1-CO2 bound to uranium.

The electron-rich, six-coordinate tris-aryloxide uranium(III) complex [((AdArO)3tacn)U(III)] [where (AdArOH)3tacn = 1,4,7-tris(3-adamantyl-5-tert-butyl-2-hydroxybenzyl)1,4,7-triazacyclononane] reacts rapidly with CO2 to yield [((AdArO)3tacn)U(IV)(CO2)], a complex in which the CO(2) ligand is linearly coordinated to the metal through its oxygen atom (eta1-OCO). The latter complex has been crystallographically and spectroscopically characterized. The inequivalent O-C-O bond lengths [1.122 angstroms (A) for the O-C bond adjacent to uranium and 1.277 A for the other], considered together with magnetization data and electronic and vibrational spectra, support the following bonding model: U(IV)=O=C*-O- <--> U(IV)-OC-O-. In these charge-separated resonance structures, the uranium center is oxidized to uranium(IV) and the CO2 ligand reduced by one electron.

Carbon Dioxide↗
PubMed2004

Synthesis and characterization of N-heterocyclic carbene complexes of uranium(III).

Reaction of [(((Ad)ArO)(3)tacn)U(III)] (1) or [((Me(3)Si)(2)N)(3)U(III)] (3) with tetramethylimidazol-2-ylidene (Me(4)IMC:) yields novel N-heterocyclic carbene complexes [(((Ad)ArO)(3)tacn)U(III)(Me(4)IMC:)] (2) and [((Me(3)Si)(2)N)(3)U(III)(Me(4)IMC:)] (4). Uranium complexes 2 and 4 represent the first examples of compounds with an N-heterocyclic carbene ligand coordinated to a low-valent uranium center. The paramagnetic complexes 1, 2, and 4 were characterized by (1)H NMR, UV-vis-NIR, and EPR spectroscopy as well as SQUID magnetization measurements and X-ray diffraction analyses. DFT studies indicate a significant degree of pi-bonding in the U(III)-carbene entity.

Journal Article↗
PubMed2003

Evidence for alkane coordination to an electron-rich uranium center.

A series of five uranium-alkane complexes of the general formula [(ArO)3tacn)U(alkane)].(cy-alkane) has been synthesized and crystallographically characterized. In all cases, X-ray diffraction studies revealed a pseudo-six-coordinate trivalent uranium core structure, [(ArO)3tacn)U], with a coordinated alkane ligand at the axial position. The average U-C bond distance to the bound alkane was determined to be 3.798 A, which is considerably shorter than the sum of the van der Waals radii of the U atom and a CH2 or CH3 unit (3.9 A). In all complexes, the alkane is coordinated in an eta2-H,C fashion.

Journal Article↗
PubMed2002

pH-dependent H2-activation cycle coupled to reduction of nitrate ion by CpIr complexes.

This paper reports a pH-dependent H2-activation [H2 (pH 1-4) --> H+ + H- (pH -1) --> 2H+ + 2e-] promoted by CpIr complexes [Cp = eta5-C5(CH3)5]. In a pH range of about 1-4, an aqueous HNO3 solution of [CpIr(III)(H2O)3]2+ (1) reacts with 3 equiv of H2 to yield a solution of [(CpIr(III))2(mu-H)3]+ (2) as a result of heterolytic H2-activation [2[1] + 3H2 (pH 1-4) --> [2] + 3H+ + 6H2O]. The hydrido ligands of 2 display protonic behavior and undergo H/D exchange with D+: [M-(H)3-M]+ + 3D+ <==>[M-(D)3-M]+ + 3H+ (where M = CpIr). Complex 2 is insoluble in a pH range of about -0.2 (1.6 M HNO3/H2O) to -0.8 (6.3 M HNO3/H2O). At pH -1 (10 M HNO3/H2O), a powder of 2 drastically reacts with HNO3 to give a solution of [CpIr(III)(NO3)2] (3) with evolution of H2, NO, and NO2 gases. D-labeling experiments show that the evolved H2 is derived from the hydrido ligands of 2. These results suggest that oxidation of the hydrido ligands of 2 [[2] + 4NO3- (pH -1) --> 2[3] + H2 + H+ + 4e-] couples to reduction of NO3- (NO3- --> NO2- --> NO). To complete the reaction cycle, complex 3 is transformed into 1 by increasing the pH of the solution from -1 to 1. Therefore, we are able to repeat the reaction cycle using 1, H2, and a pH gradient between 1 and -1. A conceivable mechanism for the H2-activation cycle with reduction of NO3- is proposed.

Journal Article↗
PubMedDate not supplied

Clinical application of zygomatic implants for rehabilitation of the severely resorbed maxilla: a clinical report.

PURPOSE: A zygomatic implant can be an effective device for rehabilitation of the severely resorbed maxilla. If zygomatic implants are used, onlay bone grafting or sinus augmentation would likely not be necessary. Where an anterior onlay bone graft is required, extension of the graft in the posterior region could be reduced. The results of the application of zygomatic implants in 9 patients and clinical evaluation of this therapy are reported. MATERIALS AND METHODS: Nine patients received a total of 15 zygomatic implants. Six to 8 months elapsed for healing before second-stage surgery was performed. Six months after prosthetic treatment, patients' opinions were solicited by means of a questionnaire. RESULTS: No implant was removed at the time of abutment connection surgery or during the follow-up period. In many cases, the zygomatic implant platform was located palatal to the alveolar ridge. However, no patients complained of any continuing speech impediment following superstructure fabrication. Computed tomograms taken before implant placement and 6 months after implant placement showed no sign of sinusitis in any patient. DISCUSSION: The zygomatic implant allows shorter treatment time and hospitalization. However, there can be some problems in the application of zygomatic implants. CONCLUSION: It is necessary to investigate long-term clinical prognosis.

Adult↗